23 results on '"del Rio, Pablo"'
Search Results
2. Impaired HDL function and endothelial barrier stability in severe anaphylaxis.
- Author
-
Fernandez-Bravo S, Canyelles M, Martín-Blázquez A, Borràs C, Nuñez-Borque E, Palacio-García L, Rodríguez Del Rio P, Betancor D, Gómez-López A, Sabaté Brescó M, Laguna JJ, Méndez-Barbero N, Rotllan N, Escolà-Gil JC, and Esteban V
- Abstract
Background: Growing evidence demonstrates the importance of high- and low-density lipoprotein cholesterol in certain immune and allergy-mediated diseases., Objective: This study aimed to evaluate levels of high- and low-density lipoprotein cholesterol and apolipoproteins (Apo) A1 and B in serum from a cohort of patients presenting with hypersensitivity reactions. We further assessed the function of high-density lipoprotein particles as well as their involvement in the molecular mechanisms of anaphylaxis., Methods: Lipid profile determination was performed in paired (acute and baseline) serum samples from 153 patients. Thirty-eight experienced a non-anaphylactic reaction and 115 had an anaphylactic reaction (88 moderate and 27 severe). Lecithin cholesterol acyl transferase activity was assessed in patient serum, and we also evaluated macrophage cholesterol efflux in response to the serum samples. Lastly, the effect of anaphylactic-derived HDL particles on the endothelial barrier was studied. For detailed Methods, please see the Methods section in this article's Online Repository at www.jacionline.org., Results: Severe anaphylactic reactions show statistically significant low levels of HDL-C, LDL-C, ApoA1, and ApoB, which points to a possible role as biomarkers. Specifically, HDL particles play a protective role in cardiovascular diseases. Using functional human sera-cell assays, we observed an impaired capacity of ApoB-depleted serum to induce macrophage cholesterol efflux in severe anaphylactic reactions. In addition, purified HDL particles from human anaphylactic sera failed to stabilize and maintain the endothelial barrier., Conclusion: These results encourage further research on HDL functions in severe anaphylaxis, which may lead to new diagnostic and therapeutic strategies., (Copyright © 2024. Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF
3. Bilastine for the treatment of allergic rhinoconjunctivitis and urticaria: results from an international Delphi study.
- Author
-
Canonica GW, Kuna P, Maurer M, Mösges R, Novak Z, Papadopoulos N, and Rodriguez Del Rio P
- Abstract
Background: Second-generation oral H
1 -antihistamines, including bilastine, represent the emerging treatments of allergic rhinitis (including rhinoconjunctivitis) and chronic urticaria in both adults and children. This study analyses available evidence supporting the use of bilastine amongst second-generation antihistamines for the symptomatic treatment of allergic rhinitis and urticaria in adults and children., Methods: Consensus amongst experts from 17 countries on the ideal treatment of rhinitis and urticaria, and the specific role of bilastine was measured by means of a modified Delphi process. A total of 12 statements were voted on by the experts using a five-point Likert scale (1 = strongly disagree; 2 = disagree; 3 = undecided; 4 = agree; 5 = strongly agree). The definition of consensus was set at a minimum of 80% concordance for 4+5 scores (agree or strongly agree)., Results: All proposed statements reached consensus, with a concordance of ≥98% for five statements and ≥96% for seven., Conclusions: The wide consensus obtained for the proposed statements suggests a prominent role for bilastine in the management of allergic rhinitis and urticaria., Competing Interests: Disclosure and potential conflicts of interest: GWC reports having received, in the last 3 years, research grants as well as lecture or advisory board fees from: Menarini, ALK-Abelló, Allergy Therapeutics, Astra Zeneca, MedImmune, Boehringer Ingelheim, Chiesi, Faes, Genentech, Guidotti, Malesci, GlaxoSmithKline, HAL Allergy, Novartis, OM Pharma, Sanofi-Aventis, Sanofi-Genzyme, Regeneron, Stallergenes, Greer, Thermo Fisher and Valeas. PK reports having receinved honoraria for lecture from Adamed, Astra Zeneca, Berlin Chemie Menarini, Boehringer Ingelheim, Celon Pharma, Faes, Glenmark, GSK, Novartis, Polpharma, Sandoz, Sanofi and Teva: PK also reports having received support for attending meetings and/or travel from Berlin Chemie Menarini and AstraZeneca. MM is or recently was a speaker and/or advisor for and/or has received research funding from Allakos, Alvotech, Amgen, Aquestive, Aralez, AstraZeneca, Astria, Bayer, BioCryst, Blueprint, Celldex, Celltrion, Centogene, CSL Behring, Evoemmune, GSK, Ipsen, Kalvista, Kyowa Kirin, Leo Pharma, Lilly, Menarini, Mitsubishi Tanabe Pharma, Moxie, Noucor, Novartis, Orion Biotechnoloy, Pharvaris, Resonance Medicine, Sanofi/Regeneron, Septerna, Takeda, Teva, Trial Form Support International AB, Third HarmonicBio, Valenza Bio, Yuhan Corporation and Zurabio. RM reports personal fees from Menarini, during the conduct of the study, as well as personal fees from ALK, Allergopharma, Allergy Therapeutics, Angelini Pharma, Bayer, Bencard, Bitop, Faes, Friulchem, GSK, HAL BV, Hexal, Klosterfrau, Johnson&Johnson, Laboratoire de la Mer, Lek, Lofarma, Meda, MSD, Mundipharma, Novartis, Nuvo, Pohl-Boskamp, PRO-AdWise, Servier, Sidroga, Stada, Stallergenes, UCB and Ursapharm; grants from ASIT biotech, Bencard, Bitop, Cassella-med GmbH & Co. KG, HAL BV, Hulka, Inmunotek, JGL, Leti, Lofarma, Optima, Sanofi, Stallergenes and Ursapharm; non-financial support from Atmos, Bionorica, Ferrero, JGL, Lofarma, Novartis, Otonomy and Roxall, all outside the submitted work. ZN reports having received consulting fees, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, educational events from AbbVi Pharma, AstraZeneca, Berlin-Chemie/A. Menarini, Boehringer, Chiesi, GlaxoSmithKline, Novartis, Orion Pharma and Sandoz, as well as support for attending meetings and/or travel from Berlin-Chemie/A. Menarini; ZN also reports participation on a Data Safety Monitoring Board or Advisory Board for AbbVi Pharma, AstraZeneca, Berlin-Chemie/A. Menarini, GlaxoSmithKline, Novartis and Orion Pharma. NGP reports having received grants from Capricare, Nestle, Numil, REG and Vianex; NGP also reports having received consulting fees from Abbott, Abbvie, AstraZeneca, GSK, HAL, Medscape, Menarini/Faes Farma, Mylan, Novartis, Nutricia, OM Pharma and Regeneron/Sanofi. PRdR has been a speaker for Aimmune Therapeutics, Allergy Group, ALK-Abelló, DBV, Faes, GSK, HAL, Leti, Merck and Novartis. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2024/04/dic.2024-2-3-COI.pdf, (Copyright © 2024 Canonica GW, Kuna P, Maurer M, Mösges R, Novak Z, Papadopoulos N, Rodriguez del Rio P, the Delphi Study Group.)- Published
- 2024
- Full Text
- View/download PDF
4. Core Outcome Set for IgE-mediated food allergy clinical trials and observational studies of interventions: International Delphi consensus study 'COMFA'.
- Author
-
Demidova A, Drewitz KP, Kimkool P, Banjanin N, Barzylovich V, Botjes E, Capper I, Castor MAR, Comberiati P, Cook EE, Costa J, Chu DK, Epstein MM, Galvin AD, Giovannini M, Girard F, Golding MA, Greenhawt M, Ierodiakonou D, Jones CJ, Khaleva E, Knibb RC, Macit-Çelebi MS, Mack DP, Mafra I, Marchisotto MJ, Mijakoski D, Nekliudov N, Özdemir C, Patel N, Pazukhina E, Protudjer JLP, Rodríguez Del Rio P, Roomet J, Sammut P, Schoos AM, Schopfer AF, Schultz F, Seylanova N, Skypala I, Sørensen M, Stoleski S, Stylianou E, Upton J, van de Veen W, Genuneit J, Boyle RJ, Apfelbacher C, and Munblit D
- Subjects
- Humans, Delphi Technique, Immunoglobulin E, Outcome Assessment, Health Care, Research Design, Treatment Outcome, Clinical Trials as Topic, Observational Studies as Topic, Food Hypersensitivity diagnosis, Food Hypersensitivity therapy, Quality of Life
- Abstract
Background: IgE-mediated food allergy (FA) is a global health concern with substantial individual and societal implications. While diverse intervention strategies have been researched, inconsistencies in reported outcomes limit evaluations of FA treatments. To streamline evaluations and promote consistent reporting, the Core Outcome Measures for Food Allergy (COMFA) initiative aimed to establish a Core Outcome Set (COS) for FA clinical trials and observational studies of interventions., Methods: The project involved a review of published clinical trials, trial protocols and qualitative literature. Outcomes found as a result of review were categorized and classified, informing a two-round online-modified Delphi process followed by hybrid consensus meeting to finalize the COS., Results: The literature review, taxonomy mapping and iterative discussions with diverse COMFA group yielded an initial list of 39 outcomes. The iterative online and in-person meetings reduced the list to 13 outcomes for voting in the formal Delphi process. One more outcome was added based on participant suggestions after the first Delphi round. A total of 778 participants from 52 countries participated, with 442 participating in both Delphi rounds. No outcome met a priori criteria for inclusion, and one was excluded as a result of the Delphi. Thirteen outcomes were brought to the hybrid consensus meeting as a result of Delphi and two outcomes, 'allergic symptoms' and 'quality of life' achieved consensus for inclusion as 'core' outcomes., Conclusion: In addition to the mandatory reporting of adverse events for FA clinical trials or observational studies of interventions, allergic symptoms and quality of life should be measured as core outcomes. Future work by COMFA will define how best to measure these core outcomes., (© 2024 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
5. Novel mediator in anaphylaxis: decreased levels of miR-375-3p in serum and within extracellular vesicles of patients.
- Author
-
Nuñez-Borque E, Fernandez-Bravo S, Rodríguez Del Rio P, Palacio-García L, Di Giannatale A, Di Paolo V, Galardi A, Colletti M, Pascucci L, Tome-Amat J, Cuesta-Herranz J, Ibañez-Sandin MD, Laguna JJ, Benito-Martin A, and Esteban V
- Subjects
- Adult, Child, Humans, Biomarkers metabolism, Anaphylaxis genetics, Anaphylaxis metabolism, MicroRNAs metabolism, Extracellular Vesicles metabolism, Circulating MicroRNA metabolism
- Abstract
Introduction: Anaphylaxis is among the most severe manifestations of allergic disorders, but its molecular basis remains largely unknown and reliable diagnostic markers are not currently available. MicroRNAs (miRNAs) regulate several pathophysiological processes and have been proposed as non-invasive biomarkers. Therefore, this study aims to evaluate their involvement in anaphylactic reaction and their value as biomarkers., Methods: Acute (anaphylaxis) and baseline (control) serum samples from 67 patients with anaphylaxis were studied. Among them, 35 were adults with drug-induced anaphylaxis, 13 adults with food-induced anaphylaxis and 19 children with food-induced anaphylaxis. The circulating serum miRNAs profile was characterized by next-generation sequencing (NGS). For this purpose, acute and baseline samples from 5 adults with drug-induced anaphylaxis were used. RNA was extracted, retrotranscribed, sequenced and the readings obtained were mapped to the human database miRBase_20. In addition, a system biology analysis (SBA) was performed with its target genes and revealed pathways related to anaphylactic mediators signaling. Moreover, functional and molecular endothelial permeability assays were conducted with miR-375-3p-transfected cells in response to cAMP., Results: A total of 334 miRNAs were identified, of which 21 were significant differentially expressed between both phases. Extracellular vesicles (EVs) were characterized by Western blot, electron microscopy and NanoSight. A decrease of miR-375-3p levels was determined by qPCR in both serum and EVs of patients with anaphylaxis (**** p <.0001). Precisely, the decrease of miR-375-3p correlated with the increase of two inflammatory cytokines: monocyte chemoattractant protein-1 (MCP-1) and granulocyte macrophage colony-stimulating factor (GM-CSF). On the other hand, functional and molecular data obtained showed that miR-375-3p partially blocked the endothelial barrier maintenance and stabilization by disassembly of cell-cell junctions exhibiting low Rac1-Cdc42 levels., Discussion: These findings demonstrate a differential serum profile of circulating miRNAs in patients with anaphylaxis and exhibit the miR-375-3p modulation in serum and EVs during drug- and food-mediated anaphylactic reactions. Furthermore, the in silico and in vitro studies show a negative role for miR-375-3p/Rac1-Cdc42 in the endothelial barrier stability., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Nuñez-Borque, Fernandez-Bravo, Rodríguez Del Rio, Palacio-García, Di Giannatale, Di Paolo, Galardi, Colletti, Pascucci, Tome-Amat, Cuesta-Herranz, Ibañez-Sandin, Laguna, Benito-Martin and Esteban.)
- Published
- 2023
- Full Text
- View/download PDF
6. Updated guidance regarding the risk of allergic reactions to COVID-19 vaccines and recommended evaluation and management: A GRADE assessment and international consensus approach.
- Author
-
Greenhawt M, Dribin TE, Abrams EM, Shaker M, Chu DK, Golden DBK, Akin C, Anagnostou A, ALMuhizi F, Alqurashi W, Arkwright P, Baldwin JL, Banerji A, Bégin P, Ben-Shoshan M, Bernstein J, Bingemann TA, Bindslev-Jensen C, Blumenthal K, Byrne A, Cahill J, Cameron S, Campbell D, Campbell R, Cavender M, Chan ES, Chinthrajah S, Comberiati P, Eastman JJ, Ellis AK, Fleischer DM, Fox A, Frischmeyer-Guerrerio PA, Gagnon R, Garvey LH, Grayson MH, Isabwe GAC, Hartog N, Hendron D, Horner CC, Hourihane JO, Iglesia E, Kan M, Kaplan B, Katelaris CH, Kim H, Kelso JM, Khan DA, Lang D, Ledford D, Levin M, Lieberman JA, Loh R, Mack DP, Mazer B, Mody K, Mosnaim G, Munblit D, Mustafa SS, Nanda A, Nathan R, Oppenheimer J, Otani IM, Park M, Pawankar R, Perrett KP, Peter J, Phillips EJ, Picard M, Pitlick M, Ramsey A, Rasmussen TH, Rathkopf MM, Reddy H, Robertson K, Rodriguez Del Rio P, Sample S, Sheshadri A, Sheik J, Sindher SB, Spergel JM, Stone CA, Stukus D, Tang MLK, Tracy JM, Turner PJ, Vander Leek TK, Wallace DV, Wang J, Wasserman S, Weldon D, Wolfson AR, Worm M, and Yacoub MR
- Subjects
- Humans, COVID-19 Vaccines adverse effects, GRADE Approach, Consensus, Vaccine Excipients, Excipients, COVID-19 prevention & control, Hypersensitivity, Immediate, Anaphylaxis
- Abstract
This guidance updates 2021 GRADE (Grading of Recommendations Assessment, Development and Evaluation) recommendations regarding immediate allergic reactions following coronavirus disease 2019 (COVID-19) vaccines and addresses revaccinating individuals with first-dose allergic reactions and allergy testing to determine revaccination outcomes. Recent meta-analyses assessed the incidence of severe allergic reactions to initial COVID-19 vaccination, risk of mRNA-COVID-19 revaccination after an initial reaction, and diagnostic accuracy of COVID-19 vaccine and vaccine excipient testing in predicting reactions. GRADE methods informed rating the certainty of evidence and strength of recommendations. A modified Delphi panel consisting of experts in allergy, anaphylaxis, vaccinology, infectious diseases, emergency medicine, and primary care from Australia, Canada, Europe, Japan, South Africa, the United Kingdom, and the United States formed the recommendations. We recommend vaccination for persons without COVID-19 vaccine excipient allergy and revaccination after a prior immediate allergic reaction. We suggest against >15-minute postvaccination observation. We recommend against mRNA vaccine or excipient skin testing to predict outcomes. We suggest revaccination of persons with an immediate allergic reaction to the mRNA vaccine or excipients be performed by a person with vaccine allergy expertise in a properly equipped setting. We suggest against premedication, split-dosing, or special precautions because of a comorbid allergic history., (Crown Copyright © 2023. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
7. CHOICE international survey: Clusters of allergen immunotherapy prescription from French and Spanish cohorts.
- Author
-
Rodriguez Del Rio P, Caimmi D, Rico Nieto P, Vidal C, Moreno C, González-Fernández MT, Tomás-Pérez M, Beristain A, Bosse I, Trinh HB, Casale TB, Demoly P, and Calderon MA
- Abstract
Background: There is no description of the drivers of prescription for allergen immunotherapy (AIT) for respiratory allergic diseases., Methods: A prospective, multicentre, observational, non-interventional real-life study was performed in France and Spain for 20 months. Data were gathered using 2 different questionnaires, anonymously collected in an online platform. No names of AIT products were recorded. Multivariate analysis and unsupervised cluster analysis were performed., Results: One hundred and three physicians (50.5% from Spain and 49.5% from France) reported 1735 patients (433 in France and 1302 in Spain), 47.9% males, 64.8% adults with a mean age 26.2 years old. They suffered from allergic rhinitis (99%), allergic conjunctivitis (70.4%), allergic asthma (51.8%), atopic dermatitis (13.9%), and food allergy (9.9%). A clustering analysis based on 13 predefined relevant variables for AIT-prescription identified 5 different clusters, each of them including information regarding doctor's profile and patient demographics, baseline disease characteristics, and main AIT indication: 1) Looking at the future: focusing on asthma prevention (n = 355), 2) Efficacy after discontinuation of AIT (n = 293), 3) Fighting severe allergic disease (n = 322), 4) Looking at the present, facing current symptoms (n = 265) and 5) Doctor's own clinical experience (n = 500). Each one of these clusters have specific patients' and doctors' characteristics, representing distinctive AIT prescription drivers., Conclusion: Using data-driven analysis, we identified for the first time some reasons and patterns of AIT prescriptions in real-life clinical settings. There is no uniform indication for prescribing AIT, which varies amongst patients and doctors with multiple but specific drivers, taking into account several relevant parameters., (© 2023 The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
8. WAO consensus on DEfinition of Food Allergy SEverity (DEFASE).
- Author
-
Arasi S, Nurmatov U, Dunn-Galvin A, Roberts G, Turner PJ, Shinder SB, Gupta R, Eigenmann P, Nowak-Wegrzyn A, Ansotegui IJ, Rivas MF, Petrou S, Tanno LK, Vazquez-Ortiz M, Vickery B, Wong G, Alvaro-Lozano M, Asaria M, Begin P, Bozzola M, Boyle R, Brough H, Cardona V, Chinthrajah RS, Cianferoni A, Deschildre A, Fleischer D, Gazzani F, Gerdts J, Giannetti M, Greenhawt M, Guzmán MA, Hossny E, Kauppi P, Jones C, Lucidi F, Monge Ortega OP, Munblit D, Muraro A, Pajno G, Podestà M, Rodriguez Del Rio P, Said M, Santos A, Shaker M, Szajewska H, Venter C, Warren C, Winders T, Ebisawa M, and Fiocchi A
- Abstract
Background: While several scoring systems for the severity of anaphylactic reactions have been developed, there is a lack of consensus on definition and categorisation of severity of food allergy disease as a whole., Aim: To develop an international consensus on the severity of food allergy (DEfinition of Food Allergy Severity, DEFASE) scoring system, to be used globally., Methods Phase 1: We conducted a mixed-method systematic review (SR) of 11 databases for published and unpublished literature on severity of food allergy management and set up a panel of international experts., Phase 2: Based on our findings in Phase 1, we drafted statements for a two-round modified electronic Delphi (e-Delphi) survey. A purposefully selected multidisciplinary international expert panel on food allergy (n = 60) was identified and sent a structured questionnaire, including a set of statements on different domains of food allergy severity related to symptoms, health-related quality of life, and economic impact. Participants were asked to score their agreement on each statement on a 5-point Likert scale ranging from "strongly agree" to "strongly disagree". Median scores and percentage agreements were calculated. Consensus was defined a priori as being achieved if 70% or more of panel members rated a statement as "strongly agree" to "agree" after the second round. Based on feedback, 2 additional online voting rounds were conducted., Results: We received responses from 92% of Delphi panel members in round 1 and 85% in round 2. Consensus was achieved on the overall score and in all of the 5 specific key domains as essential components of the DEFASE score., Conclusions: The DEFASE score is the first comprehensive grading of food allergy severity that considers not only the severity of a single reaction, but the whole disease spectrum. An international consensus has been achieved regarding a scoring system for food allergy disease. It offers an evaluation grid, which may help to rate the severity of food allergy. Phase 3 will involve validating the scoring system in research settings, and implementing it in clinical practice., (© 2023 The Authors.)
- Published
- 2023
- Full Text
- View/download PDF
9. Personalized diagnostic approach and indirect quantification of extravasation in human anaphylaxis.
- Author
-
Nuñez-Borque E, Betancor D, Pastor-Vargas C, Fernández-Bravo S, Martin-Blazquez A, Casado-Navarro N, López-Domínguez D, Gómez-López A, Rodriguez Del Rio P, Tramón P, Beitia JM, Moreno-Aguilar C, González-de-Olano D, Goikoetxea MJ, Ibáñez-Sandín MD, Laguna JJ, Cuesta-Herranz J, and Esteban V
- Subjects
- Humans, Tryptases, Serum Albumin, Human, Anaphylaxis diagnosis, Anaphylaxis etiology
- Abstract
Background: Anaphylaxis is the most acute and life-threatening manifestation of allergic disorders. Currently, there is a need to improve its medical management and increase the understanding of its molecular mechanisms. This study aimed to quantify the extravasation underlying human anaphylactic reactions and propose new theragnostic approaches., Methods: Molecular determinations were performed in paired serum samples obtained during the acute phase and at baseline from patients presenting with hypersensitivity reactions. These were classified according to their severity as Grades 1, 2 and 3, the two latter being considered anaphylaxis. Tryptase levels were measured by ImmunoCAP, and serum protein concentration was quantified by Bradford assay. Human serum albumin (HSA) and haemoglobin beta subunit (HBB) levels were determined by Western blot and polyacrylamide gel electrophoresis, respectively., Results: A total of 150 patients were included in the study. Of them, 112 had experienced anaphylaxis (83 and 29 with Grade 2 and 3 reactions, respectively). Tryptase diagnostic efficiency substantially improved when considering patients' baseline values (33%-54%) instead of the acute value threshold (21%). Serum protein concentration and HSA significantly decreased in anaphylaxis (p < .0001). HSA levels dropped with the severity of the reaction (6% and 15% for Grade 2 and 3 reactions, respectively). Furthermore, HBB levels increased during the acute phase of all hypersensitivity reactions (p < .0001)., Conclusions: For the first time, the extravasation underlying human anaphylaxis has been evaluated based on the severity of the reaction using HSA and protein concentration measurements. Additionally, our findings propose new diagnostic and potential therapeutic approaches for this pathological event., (© 2022 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
10. Allergic diseases and immunodeficiencies in children, lessons learnt from COVID-19 pandemic by 2022: A statement from the EAACI-section on pediatrics.
- Author
-
Munblit D, Greenhawt M, Brough HA, Pushkareva A, Karimova D, Demidova A, Warner JO, Kalayci O, Sediva A, Untersmayr E, Rodriguez Del Rio P, Vazquez-Ortiz M, Arasi S, Alvaro-Lozano M, Tsabouri S, Galli E, Beken B, and Eigenmann PA
- Subjects
- Child, Humans, Pandemics, Post-Acute COVID-19 Syndrome, COVID-19 epidemiology, Hypersensitivity, Asthma epidemiology, Immunologic Deficiency Syndromes
- Abstract
By the April 12, 2022, the COVID-19 pandemic had resulted in over half a billion people being infected worldwide. There have been 6.1 million deaths directly due to the infection, but the pandemic has had many more short- and long-term pervasive effects on the physical and mental health of the population. Allergic diseases are among the most prevalent noncommunicable chronic diseases in the pediatric population, and health-care professionals and researchers were seeking answers since the beginning of pandemic. Children are at lower risk of developing severe COVID-19 or dying from infection. Allergic diseases are not associated with a higher COVID-19 severity and mortality, apart from severe/poorly controlled asthma. The pandemic disrupted routine health care, but many mitigation strategies, including but not limited to telemedicine, were successfully implemented to continue delivery of high-standard care. Although children faced a multitude of pandemic-related issues, allergic conditions were effectively treated remotely while reduction in air pollution and lack of contact with outdoor allergens resulted in improvement, particularly respiratory allergies. There is no evidence to recommend substantial changes to usual management modalities of allergic conditions in children, including allergen immunotherapy and use of biologicals. Allergic children are not at greater risk of multisystem inflammatory syndrome development, but some associations with Long COVID were reported, although the data are limited, and further research is needed. This statement of the EAACI Section on Pediatrics provides recommendations based on the lessons learnt from the pandemic, as available evidence., (© 2022 The Authors. Pediatric Allergy and Immunology published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
11. A Pragmatic Primary Practice Approach to Using Specific IgE in Allergy Testing in Asthma Diagnosis, Management, and Referral.
- Author
-
Demoly P, Liu AH, Rodriguez Del Rio P, Pedersen S, Casale TB, and Price D
- Abstract
Asthma afflicts an estimated 339 million people globally and is associated with ill health, disability, and early death. Strong risk factors for developing asthma are genetic predisposition and environmental exposure to inhaled substances that may provoke allergic reactions. Asthma guidelines recommend identifying causal or trigger allergens with specific IgE (sIgE) testing after a diagnosis of asthma has been made. Allergy testing with sIgE targets subpopulations of patients considered at high risk, such as those with frequent exacerbations, emergency visits or hospitalizations, or uncontrolled symptoms. Specific recommendations apply to preschool children, school-age children, patients with persistent or difficult-to-control asthma, patients needing oral corticosteroids or high-dose inhaled steroids, patients seeking understanding and guidance about their disease, and candidates for advanced therapies (biologics, allergen immunotherapy). Allergen skin testing is common in specialized settings but less available in primary care. Blood tests for total and sIgE are accessible and yield quantifiable results for tested allergens, useful for detecting sensitization. Results are interpreted in the context of the patient's clinical presentation, age, and relevant allergen exposures. Incorporating sIgE testing into asthma management adds objective information to identify specific allergies and can guide personalized treatment plans, which reinforce patient-doctor communication. Test results can also be used to predict exacerbations and response to therapies. Additional diagnostic information can be gleaned from (i) eosinophil count ≥300 μL, which significantly increases the odds of having exacerbations, and emerging eosinophil biomarkers (eg, eosinophil-derived neurotoxin), which can be measured in plasma or serum samples, and (ii) fractional exhaled nitric oxide (FeNO), with values ≥25 ppb regarded as the cutoff for diagnosis, evaluating inhaled corticosteroid response, and of probable response to anti-IgE, anti-IL4 and anti-IL5 receptor biologics. Referral to asthma/allergy specialists is warranted when the initial diagnosis is uncertain, and when asthma symptoms, impairment, or exacerbations are repeated or severe., Competing Interests: David Price has advisory board membership with AstraZeneca, Boehringer Ingelheim, Chiesi, Mylan, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, Thermofisher; consultancy agreements with Airway Vista Secretariat, AstraZeneca, Boehringer Ingelheim, Chiesi, EPG Communication Holdings Ltd, FIECON Ltd, Fieldwork International, GlaxoSmithKline, Mylan, Mundipharma, Novartis, OM Pharma SA, PeerVoice, Phadia AB, Spirosure Inc, Strategic North Limited, Synapse Research Management Partners S.L., Talos Health Solutions, Theravance and WebMD Global LLC; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd) from AstraZeneca, Boehringer Ingelheim, Chiesi, Mylan, Novartis, Regeneron Pharmaceuticals, Respiratory Effectiveness Group, Sanofi Genzyme, Theravance and UK National Health Service; payment for lectures/speaking engagements from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Mylan, Mundipharma, Novartis, Regeneron Pharmaceuticals and Sanofi Genzyme; payment for travel/accommodation/meeting expenses from AstraZeneca, Boehringer Ingelheim, Mundipharma, Mylan, Novartis, Thermofisher; stock/stock options from AKL Research and Development Ltd which produces phytopharmaceuticals; owns 74% of the social enterprise Optimum Patient Care Ltd (Australia and UK) and 92.61% of Observational and Pragmatic Research Institute Pte Ltd (Singapore); 5% shareholding in Timestamp which develops adherence monitoring technology; is peer reviewer for grant committees of the UK Efficacy and Mechanism Evaluation programme, and Health Technology Assessment; and was an expert witness for GlaxoSmithKline. Dr. Rodriguez del Rio reports personal fees from ALK Abello, grants and personal fees from Aimmune Therapeutics, grants from Merck, personal fees from GSK, personal fees from FAES, personal fees from Novartis, personal fees from Thermo Fisher, personal fees from LETI Pharma, personal fees from Allergy Therapeutics, personal fees from Miravo, outside the submitted work. Dr Liu reports consultant fees paid to his university employer from Thermo Fisher; Avillion and Labcorp; research grants paid to his university from ResMed Propeller Health, Revenio, and Avillion. Dr Casale reports consulting fees from Thermo Fisher Scientific, Genentech, Novartis, outside the submitted work. Dr. Pedersen reports personal fees from AstraZeneca, personal fees from ALK, personal fees from Thermo Fisher Scientific, outside the submitted work. The authors report no other conflicts of interest in this work., (© 2022 Demoly et al.)
- Published
- 2022
- Full Text
- View/download PDF
12. Asthma and Allergy: Unravelling a Tangled Relationship with a Focus on New Biomarkers and Treatment.
- Author
-
Rodriguez Del Rio P, Liu AH, Borres MP, Södergren E, Iachetti F, and Casale TB
- Subjects
- Allergens, Biomarkers, Child, Humans, Respiratory Sounds, Asthma diagnosis, Asthma therapy, Hypersensitivity diagnosis, Hypersensitivity therapy
- Abstract
Asthma is a major driver of health care costs across ages. Despite widely disseminated asthma-treatment guidelines and a growing variety of effective therapeutic options, most patients still experience symptoms and/or refractoriness to standard of care treatments. As a result, most patients undergo a further intensification of therapy to optimize symptom control with a subsequent increased risk of side effects. Raising awareness about the relevance of evaluating aeroallergen sensitizations in asthmatic patients is a key step in better informing clinical practice while new molecular tools, such as the component resolved diagnosis, may be of help in refining the relationship between sensitization and therapeutic recommendations. In addition, patient care should benefit from reliable, easy-to-measure and clinically accessible biomarkers that are able to predict outcome and disease monitoring. To attain a personalized asthma management and to guide adequate treatment decisions, it is of paramount importance to expand clinicians' knowledge about the tangled relationship between asthma and allergy from a molecular perspective. Our review explores the relevance of allergen testing along the asthma patient's journey, with a special focus on recurrent wheezing children. Here, we also discuss the unresolved issues regarding currently available biomarkers and summarize the evidence supporting the eosinophil-derived neurotoxin as promising biomarker.
- Published
- 2022
- Full Text
- View/download PDF
13. Real-life report of allergen immunotherapy management during the COVID-19 outbreak in France and Spain.
- Author
-
Rodriguez Del Rio P, Caimmi D, Rico P, Vidal C, Carmen M, Pintoiu IM, Beitia Mazuecos JM, Gonzalez de Olano D, Cuesta Alvaro P, Demoly P, and Calderon MA
- Subjects
- France, Humans, Practice Patterns, Physicians', SARS-CoV-2, Spain, Anti-Allergic Agents therapeutic use, COVID-19, Desensitization, Immunologic, Hypersensitivity therapy, Quarantine
- Published
- 2022
- Full Text
- View/download PDF
14. Increased miR-21-3p and miR-487b-3p serum levels during anaphylactic reaction in food allergic children.
- Author
-
Nuñez-Borque E, Fernandez-Bravo S, Rodriguez Del Rio P, Alwashali EM, Lopez-Dominguez D, Gutierrez-Blazquez MD, Laguna JJ, Tome-Amat J, Gallego-Delgado J, Gomez-Lopez A, Betancor D, Cuesta-Herranz J, Ibañez-Sandin MD, Benito-Martin A, and Esteban V
- Subjects
- Adolescent, Biomarkers, Child, Endothelial Cells, Gene Expression Profiling, High-Throughput Nucleotide Sequencing, Humans, Anaphylaxis, MicroRNAs
- Abstract
Background: Anaphylaxis is the most severe manifestation of allergic disorders. The poor knowledge of its molecular mechanisms often leads to under-diagnosis. MicroRNAs (miRNA) regulate physiologic and pathologic processes, and they have been postulated as promising diagnostic markers. The main objectives of this study were to characterize the human miRNA profile during anaphylaxis and to assess their capacity as diagnostic markers and determine their participation in the molecular mechanisms of this event., Methods: The miRNA serum profiles from the acute and baseline phase of 5 oral food-challenged anaphylactic children (<18 years old) were obtained by next-generation sequencing (NGS). From the panel of statistically significant miRNAs obtained, several candidates were selected and analyzed in 19 anaphylactic children by qPCR. We performed system biology analysis (SBA) on their target genes to identify main functions and canonical pathways. A functional in vitro assay was carried out incubating endothelial cells (ECs) in anaphylactic conditions., Results: The NGS identified 389 miRNAs among which 41 were significantly different between acute and baseline samples. The high levels of miR-21-3p (fold change = 2.28, P = .006) and miR-487b-3p (fold change = 1.04, P = .039) observed by NGS in acute serum samples were confirmed in a larger group of 19 patients. The SBA revealed molecular pathways related to the inflammation and immune system regulation. miR-21-3p increased intracellularly and in acute phase serum after EC stimulation., Conclusions: These findings provide, for the first time, some insights into the anaphylactic miRNA serum profile in children and point to miR-21-3p and miR-487b-3p as candidate biomarkers. Furthermore, the SBA revealed a possible implication of these molecules in the underlying molecular mechanisms. Moreover, ECs increased miR-21-3p intracellularly and released it to the environment in response to anaphylaxis., (© 2021 The Authors. Pediatric Allergy and Immunology published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
15. Outcomes for clinical trials of food allergy treatments.
- Author
-
Sim K, Mijakoski D, Stoleski S, Del Rio PR, Sammut P, Le TM, Munblit D, and Boyle RJ
- Subjects
- Desensitization, Immunologic, Humans, Quality of Life, Treatment Outcome, Clinical Trials as Topic standards, Food Hypersensitivity therapy, Outcome Assessment, Health Care standards
- Abstract
Objective: Food allergy is a common condition that can have a significant impact on the quality of life of affected individuals and their caregivers. Recent years have witnessed an increased effort to identify new treatments for food allergy. Here, we review the need to identify core outcomes for measurement in clinical trials of food allergy treatments., Data Sources: We reviewed the literature regarding core outcome set development, the important role that these play in prioritizing patient-relevant outcomes, and the potential for core outcomes to accelerate the path to product marketing by allowing prompt and reliable evidence synthesis after trial publication., Study Selections: We reviewed recent clinical trials of food allergy treatments to understand which outcomes have previously been measured, and also reviewed available core outcome set initiatives for other allergic conditions to understand which other outcomes might be explored in future trials., Results: Clinical trials of food allergy treatments have largely focused on outcomes that are relevant to investigators and commercial investors, especially the threshold of reactivity and immunologic changes. Future trials should consider addressing patient-important outcomes and should report the experiences of both adult and child participants and their caregivers., Conclusion: There is a pressing need for core outcome set development for food allergy treatment trials., (Copyright © 2020. Published by Elsevier Inc.)
- Published
- 2020
- Full Text
- View/download PDF
16. Alkaline sulfonation and thermomechanical pulping pretreatment of softwood chips and pellets to enhance enzymatic hydrolysis.
- Author
-
Wu J, Chandra R, Takada M, Del Rio P, Kim KH, Kim CS, Liu LY, Renneckar S, and Saddler J
- Subjects
- Cellulose, Hydrolysis, Lignin, Cellulase, Wood
- Abstract
To assess the impact of alkalinity on sulfonation and the enzyme-mediated hydrolysis of softwood cellulose, Lodgepole pine chips were impregnated with 8% sodium sulfite and increasing loadings of sodium carbonate before thermomechanical pulping. It was apparent that alkali addition enhanced lignin sulfonation with an additional 4% loading of sodium carbonate proving optimal. TEM indicated that sulfonation predominantly occurred within the secondary-cell-wall lignin, increasing cellulose accessibility to the cellulase enzymes. Although increasing alkalinity did not significantly enhance lignin sulfonation, likely due to the lower acetyl content of the softwood chips, it increases mannan solubilization. Despite their smaller particle size, softwood pellets were more poorly sulfonated, probably due to their higher lignin content and lower amount of acid groups. This more condensed lignin structure was confirmed by 2D-NMR and GPC analyses which indicated that the EMAL derived from softwood pellets contained less native β-O-4 linkages and had a higher molecular weight., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2020 Elsevier Ltd. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
17. The Role of Aeroallergen Sensitization Testing in Asthma Management.
- Author
-
Casale TB, Pedersen S, Rodriguez Del Rio P, Liu AH, Demoly P, and Price D
- Subjects
- Allergens, Humans, Monitoring, Physiologic, Asthma diagnosis, Asthma therapy, Hypersensitivity
- Abstract
Asthma is a global disease affecting almost 400 million people. Simultaneously, the overall burden of allergies is increasing. Although allergies are frequent and commonly recognized triggers of asthma severity and exacerbations, the majority of patients with asthma are not investigated for their underlying aeroallergen sensitizations, despite the potentially preventable consequences and therapeutic options. This review summarizes the current state of aeroallergen sensitization testing for people with asthma. We describe who should be tested and why, how testing can be used to optimize asthma management, list barriers to implementation of effective asthma management strategies, and make recommendations for improving asthma/allergy management by aeroallergen testing. Establishing a diagnosis of asthma and determining whether there is an allergic component is fundamental to an effective treatment plan. Moreover, moving from severity-based to phenotype-based asthma care can improve the care of asthma and allergic diseases. Timely diagnosis of aeroallergen sensitizations forms the basis for individualized treatment plans, which may include allergen remediation strategies when appropriate, and allergen immunotherapy, the only immunomodulating therapy for allergic asthma. Finally, the advent of biologics will expand the number of patients who can benefit from treatment, with decreased symptoms and disease remission a possibility for the first time., (Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
18. Managing childhood allergies and immunodeficiencies during respiratory virus epidemics - The 2020 COVID-19 pandemic: A statement from the EAACI-section on pediatrics.
- Author
-
Brough HA, Kalayci O, Sediva A, Untersmayr E, Munblit D, Rodriguez Del Rio P, Vazquez-Ortiz M, Arasi S, Alvaro-Lozano M, Tsabouri S, Galli E, Beken B, and Eigenmann PA
- Subjects
- Academies and Institutes, Adolescent, COVID-19, Child, Child, Preschool, Europe, Humans, Infant, Practice Guidelines as Topic, SARS-CoV-2, Betacoronavirus, Coronavirus Infections prevention & control, Hypersensitivity therapy, Immunologic Deficiency Syndromes therapy, Pandemics prevention & control, Pediatrics methods, Pneumonia, Viral prevention & control
- Abstract
While the world is facing an unprecedented pandemic with COVID-19, patients with chronic diseases need special attention and if warranted adaptation of their regular treatment plan. In children, allergy and asthma are among the most prevalent non-communicable chronic diseases, and healthcare providers taking care of these patients need guidance. At the current stage of knowledge, children have less severe symptoms of COVID-19, and severe asthma and immunodeficiency are classified as risk factors. In addition, there is no evidence that currently available asthma and allergy treatments, including antihistamines, corticosteroids, and bronchodilators, increase the risk of severe disease from COVID-19. Most countries affected by COVID-19 have opted for nationwide confinement, which means that communication with the primary clinician is often performed by telemedicine. Optimal disease control of allergic, asthmatic, and immunodeficient children should be sought according to usual treatment guidelines. This statement of the EAACI Section on Pediatrics puts forward six recommendations for the management of childhood allergies and immunodeficiencies based on six underlying facts and existing evidence., (© 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.)
- Published
- 2020
- Full Text
- View/download PDF
19. Epidemiology of multiple sclerosis and vitamin D levels in Lanzarote, Canary Islands, Spain.
- Author
-
Pérez-Pérez S, Eguia Del Rio P, Domínguez-Mozo MI, García-Martínez MÁ, Zapata-Ramos MF, Torrejon MJ, Arroyo R, and Alvarez-Lafuente R
- Abstract
Background: Low levels of 25-hydroxyvitamin D (25(OH)D) have been described as one of the possible environmental factors involved in multiple sclerosis (MS) etiopathogenesis., Objectives: To study epidemiology of MS and 25(OH)D serum levels of patients in Lanzarote (29°02'06″N), a region with high ultraviolet radiation values during the whole year which is located far apart from Iberian Peninsula (36°-43°N), but without genetic/ethnic differences with it., Methods: Incidence in Lanzarote was assessed according to McDonald 2005 criteria between January 2008 and December 2015 and prevalence date was 12/31/15. For 25(OH)D serum levels analyses, samples from 60 MS patients and 60 healthy donors (HD) were collected monthly in a one-year prospective study., Results: The prevalence of MS in Lanzarote was 50.0/100,000 and the incidence per year was 2.5/100,000. Median 25(OH)D levels values were 29.1 ng/ml for MS patients (maximum = 36.1 ng/ml, minimum = 22.5 ng/ml) and 27.1 ng/ml for HD (maximum = 34.8 ng/ml, minimum = 22.8 ng/ml). There were no significant differences between 25(OH)D serum levels between MS patients and HD., Conclusions: Lanzarote possesses lower prevalence and incidence values than peninsular Spain. Moreover, 25(OH)D serum levels do not differ between MS patients and HD., Competing Interests: Silvia Pérez-Pérez has a research contract from MECD (FPU16/00969) and has no competing interests. Pablo Eguia del Rio has received honoraria for speaking, personal fees and non-financial support (Merck-Serono, TEVA, Sanofi-Genzyme, Novartis and Biogen-Idec) and received honoraria for a clinical trial (Roche). María Ángel García-Martínez has a technician contract from REEM (RD12/0032/0009) and has no competing interests. Rafael Arroyo reports grants, personal fees and non-financial support (Merck-Serono, Biogen-Idec, Novartis, Sanofi-Genzime, TEVA, Roche). Roberto Álvarez-Lafuente has a research contract from IdISSC and received travel funding and/or speaker honoraria (Merck-Serono, Novartis, TEVA, Sanofi-Genzime, Biogen-Idec, Roche), and research support (Merck-Serono, TEVA, Sanofi-Genzime, Novartis, Biogen-Idec). María Inmaculada Domínguez-Mozo, María Francisca Zapata-Ramos, María José Torrejón have no competing interests., (©2019 Pérez-Pérez et al.)
- Published
- 2019
- Full Text
- View/download PDF
20. HEART RATE AND INDIRECT BLOOD PRESSURE RESPONSES TO FOUR DIFFERENT FIELD ANESTHETIC PROTOCOLS IN WILD-BORN CAPTIVE CHIMPANZEES (PAN TROGLODYTES).
- Author
-
Atencia R, Stöhr EJ, Drane AL, Stembridge M, Howatson G, Del Rio PRL, Feltrer Y, Tafon B, Redrobe S, Peck B, Eng J, Unwin S, Sanchez CR, and Shave RE
- Subjects
- Anesthesia, Anesthetics administration & dosage, Anesthetics, Combined administration & dosage, Animals, Animals, Zoo, Drug Combinations, Female, Hypnotics and Sedatives administration & dosage, Isoflurane administration & dosage, Isoflurane pharmacology, Ketamine administration & dosage, Ketamine pharmacology, Male, Medetomidine administration & dosage, Medetomidine pharmacology, Tiletamine administration & dosage, Tiletamine pharmacology, Zolazepam administration & dosage, Zolazepam pharmacology, Anesthetics pharmacology, Anesthetics, Combined pharmacology, Blood Pressure drug effects, Heart Rate drug effects, Hypnotics and Sedatives pharmacology, Pan troglodytes
- Abstract
Limited data are available on hemodynamic responses to anesthetic protocols in wild-born chimpanzees (Pan troglodytes). Accordingly, this study characterized the heart rate (HR) and blood pressure responses to four anesthetic protocols in 176 clinically healthy, wild-born chimpanzees undergoing routine health assessments. Animals were anesthetized with medetomidine-ketamine (MK) (n = 101), tiletamine-zolazepam (TZ) (n = 30), tiletamine-zolazepam-medetomidine (TZM) (n = 24), or medetomidine-ketamine (maintained with isoflurane) (MKI) (n = 21). During each procedure, HR, systolic blood pressure (SBP), and diastolic blood pressure (DBP) were regularly recorded. Data were grouped according to anesthetic protocol, and mean HR, SBP, and DBP were calculated. Differences between mean HR, SBP, and DBP for each anesthetic protocol were assessed using the Kruskall-Wallis test and a Dunn multiple comparisons post hoc analysis. To assess the hemodynamic time course response to each anesthetic protocol, group mean data (±95% confidence interval [CI]) were plotted against time postanesthetic induction. Mean HR (beats/min [CI]) was significantly higher in TZ (86 [80-92]) compared to MKI (69 [61-78]) and MK (62 [60-64]) and in TZM (73 [68-78]) compared to MK. The average SBP and DBP values (mm Hg [CI]) were significantly higher in MK (130 [126-134] and 94 [91-97]) compared to TZ (104 [96-112] and 58 [53-93]) and MKI (113 [103-123] and 78 [69-87]) and in TZM (128 [120-135] and 88 [83-93]) compared to TZ. Time course data were markedly different between protocols, with MKI showing the greatest decline over time. Both the anesthetic protocol adopted and the timing of measurement after injection influence hemodynamic recordings in wild-born chimpanzees and need to be considered when monitoring or assessing cardiovascular health.
- Published
- 2017
- Full Text
- View/download PDF
21. Physicians' experience and opinion on contraindications to allergen immunotherapy: The CONSIT survey.
- Author
-
Rodríguez Del Rio P, Pitsios C, Tsoumani M, Pfaar O, Paraskevopoulos G, Gawlik R, Valovirta E, Larenas-Linnemann D, Demoly P, and Calderón MA
- Subjects
- Clinical Competence, Desensitization, Immunologic methods, Humans, Public Health Surveillance, Desensitization, Immunologic adverse effects, Expert Testimony, Physicians, Practice Patterns, Physicians', Surveys and Questionnaires
- Abstract
Background: Allergen immunotherapy (AIT) is the only disease-modifying treatment in allergy but several contraindications limit its use., Objective: To collect the outcome of using AIT in theoretically contraindicated situations in real patients in the Contraindications to Specific ImmunoTherapy (CONSIT) survey., Methods: The CONSIT is an electronic European Academy of Allergy and Clinical Immunology survey conducted to gather the safety outcomes of patients undergoing subcutaneous, sublingual, or venom AIT and the opinions of physicians on each of 17 selected conditions: children younger than 5 years; starting AIT during pregnancy; controlled severe asthma; arrhythmias; coronary disease; cancer; autoimmune disease; bone marrow and solid organ transplantation; human immunodeficiency virus and acquired immunodeficiency syndrome; previous anaphylaxis during AIT; use of β-blockers, angiotensin-converting inhibitors, cyclosporine, and methotrexate; and inability to communicate. Safety using AIT was reported in a 3-point scale: 1, "no problems"; 2, "minor problems" (requiring only dose modifications); and 3, "major problems" (AIT not tolerated). Each physician was asked about the degree of contraindication that each condition should have: no contraindication (score 1), relative contraindication (score 2), or absolute contraindication (score 3)., Results: Five hundred twenty physicians (75% Europeans, 89% allergists) reported on approximately 45,000 patients undergoing AIT with any of these conditions. Major problems were infrequent, occurring more frequently in patients with asthma (9.9%) and with previous anaphylaxis from AIT (9.5%). Regarding opinions, experienced physicians scored a significantly lower mean for all conditions than non-experienced physicians for all routes., Conclusion: Major problems were infrequent and experienced physicians were less likely to be restrictive in the use of AIT., (Copyright © 2017 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
22. Immunological cross-reactivity between olive and grass pollen: implication of major and minor allergens.
- Author
-
Cases B, Ibañez MD, Tudela JI, Sanchez-Garcia S, Del Rio PR, Fernandez EA, Escudero C, and Fernandez-Caldas E
- Abstract
Background: Grasses and olive trees are the most common sources of allergenic pollen worldwide. Although they share some allergens, there are few studies analyzing the in vitro cross-reactivity between them. The aim was to define the cross-reactivity between Olea europaea and Phleum pratense using well-characterized sera of allergic children from Madrid, Spain., Methods: 66 patients (mean age 10.32+/-4.07 years) were included in the study. All suffered from rhinoconjuntivitis and/or asthma and had a positive skin test and/or specific IgE determination to olive and grass pollen. Serum sIgE to individual allergens was conducted and sIgE against different grass species and olive was also determined by ELISA. Inhibition assays were performed using two serum sources, containing, or not, sIgE to minor allergens. Mass spectrometry analysis was performed in both extracts., Results: 59/66 (89.39%) children had a positive sIgE determination by ELISA to grasses and 57/66 (86.36%) to olive pollen. There was no significant correlation between sIgE levels to grass and olive. Inhibition assays demonstrated no cross-reactivity between P. pratense and olive pollen when using the pool containing mainly sIgE to major allergens, whereas minimal to moderate cross-reactivity was detected when the serum contained high sIgE titers to minor allergens. Proteomic analyses revealed the presence of 42 common proteins in grasses and olive pollens., Conclusion: No in vitro cross-reactivity was observed when sIgE was mainly directed to major allergens. In our population, sensitization to olive and grasses is not due to cross-reactivity. The contribution of the major allergens seems to be determinant.
- Published
- 2014
- Full Text
- View/download PDF
23. Asthma diagnosis and treatment - 1010. Lung function tests in exercise-induced asthma among pediatric population.
- Author
-
Garcia SS, Rodriguez Del Rio P, Escudero C, and Ibañez MD
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.